PRESS RELEASES
2024-09-20 09:00
Lipum reports that the last patient has been enrolled in the ongoing phase 1 study with SOL-116
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in...
2024-08-19 08:30
Lipum welcomes Dr. Peter Hovstadius as Chief Medical Officer
Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD...
2024-08-15 08:30
Lipum to participate in the following upcoming events and meetings
Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced...
2024-08-09 08:00
Lipum AB – interim report Q2 for the period January-June 2024
Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-08-08 13:45
Lipum has received a negative preliminary report regarding the audit of the Horizon 2020 project
Lipum AB (publ) received in August 2018 a M€ 2.2 / MSEK 23 grant from the European Commission innovation program Horizon 2020. The successful project...
2024-06-18 08:30
LIPUM REPORTS FURTHER PROGRESS WHERE THE MULTIPLE DOSE PART OF THE PHASE I CLINICAL STUDY IS COMPLETED
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days...
2024-05-28 08:00
Lipum AB – interim report Q1 for the period January-March 2024
Lipum AB (publ) has published the interim report Q1 for the period January-March 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-05-06 09:00
Lipum receives loan commitment of SEK 20 million
Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market...
2024-04-25 13:10
Lipum announces final outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-23 18:40
Lipum announces preliminary outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...